Clinical Trials Logo

Filter by:
NCT ID: NCT05742724 Recruiting - Clinical trials for Chronic Kidney Diseases

The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and Cannabidiol

POT-GFR-PK
Start date: January 11, 2023
Phase: Phase 1
Study type: Interventional

POT-GFR-PK is a single dose pharmacokinetic study oral tetrahydrocannabinol (THC) and cannabidiol (CBD) in healthy adult controls and individuals with chronic kidney disease including those treated with in-center hemodialysis.

NCT ID: NCT05742698 Active, not recruiting - Clinical trials for Frontotemporal Dementia

Nabilone for Agitation in Frontotemporal Dementia

Nabilone-FTD
Start date: March 7, 2023
Phase: Phase 2
Study type: Interventional

The primary goal of this study is to test the hypothesis that oral nabilone treatment will reduce agitation compared with placebo in patients with Frontotemporal Dementia (both behavioural variant frontotemporal dementia and primary progressive aphasia). The study population is defined as patients with probable Frontotemporal Dementia that meet the International Psychogeriatric Association criteria for agitation in cognitive disorders.

NCT ID: NCT05742009 Completed - Clinical trials for Intraocular Pressure

iCare ST500 Clinical Trial

Start date: June 5, 2023
Phase: N/A
Study type: Interventional

Clinical validation of iCare ST500 tonometer per ANSI Z80.10:2014 standard

NCT ID: NCT05741476 Recruiting - Allergy, Peanut Clinical Trials

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

VITESSE
Start date: February 21, 2023
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.

NCT ID: NCT05741216 Completed - Dry Eye Clinical Trials

Evaluation of Comfort of Ocular Lubricants in Symptomatic Contact Lens Wearers

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the ocular comfort of 3 ocular lubricants and a comparator.

NCT ID: NCT05740748 Not yet recruiting - Asthma, Allergic Clinical Trials

Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

Asthma is a condition where small inhaled particles can cause inflammation in the lung leading to constriction of airways and wheeze. Mast cells are immune cells in airways that can release chemical causing constriction of the airways and wheeze. Tezepelumab is an injectable medication that improves asthma by stopping inflammation, but the effect on mast cells is not known. Tezepelumab was approved in Canada July 2022 for treatment of severe asthma. Tezepelumab is not approved for treatment of mild asthma by any health authority, except for use in research studies like this. This study will examine the effect of tezepelumab on mast cells and airway constriction to understand the mechanisms of asthma, and which patients will benefit most from drugs like tezepelumab.

NCT ID: NCT05740670 Completed - Weight Loss Clinical Trials

The Safety and Efficacy of a Bone Broth Diet on Weight Loss in Obese Adults

Start date: January 25, 2023
Phase: N/A
Study type: Interventional

The primary objective of this study is to investigate the safety and efficacy of a bone broth diet on weight loss in obese adults. The change in weight and body mass index (BMI) following the bone broth diet will be measured from baseline at Days 22 and 50. Additionally, the safety and tolerability of the bone broth diet will be measured by the occurrence of post-emergent adverse events (AEs).

NCT ID: NCT05740566 Recruiting - Clinical trials for Small Cell Lung Cancer (SCLC)

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

DeLLphi-304
Start date: May 31, 2023
Phase: Phase 3
Study type: Interventional

The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).

NCT ID: NCT05740514 Recruiting - Clinical trials for Diabetes Mellitus, Type 1

Healthy Outcomes for Muscle With Exercise in T1D

HOME T1D
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

Over 300,000 people in Canada suffer from Type 1 Diabetes (T1D), a chronic condition whose incidence rate has been increasing in Canada every year by 5.1% (higher than the global average). While exogenous insulin injections allow those with T1D to live, it is not a cure, and those with T1D develop severe complications (kidney failure, cardiovascular disease). Strategies to regress the development of these complications, minimize healthcare system burden, and save the lives of Canadians are urgently needed. Undertaking regular exercise is an obvious strategy for those with T1D and has many well-established health benefits. Despite these benefits, adults with T1D exercise less frequently due to fear of severe hypoglycemia and a lack of knowledge of effective exercise strategies. Adding to this complexity, the investigators have recently shown that males and females elicit differential impairments in skeletal muscle metabolism in response to T1D. These differences may extend to the peripheral microvasculature and may lead to sexual dimorphism in the health benefits of exercise for those with T1D. Ultimately, developing a healthy muscle mass, including microvasculature, will help mitigate dysglycemic and dyslipidemic fluctuations and improve insulin sensitivity. The overarching purpose of this proposed study is to determine the impact of T1D on human skeletal muscle and its microvasculature over the lifespan in males and females, and its responses to exercise training and detraining.

NCT ID: NCT05740033 Recruiting - Oral Cancer Clinical Trials

Radial Forearm Donor Site Closure

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The radial forearm free flap (RFFF) is widely used in head and neck reconstruction. Its thinness, pliability, pedicle length, and vessel size are particularly suited for oropharyngeal and oral cavity reconstruction. Concerns about aesthetic and functional morbidity at the donor site have given rise to various techniques of closing the donor site, two of which are the split-thickness skin graft (STSG), taken from the thigh, and the hatchet flap, which uses a local flap within the radial forearm. This RCT will determine whether retrospectively reported improvements to aesthetic and functional outcomes for STSG patients are greater compared to hatchet flap patients.